Long term prognostic importance of late gadolinium enhancement in first-presentation non-ischaemic dilated cardiomyopathy

Karthigesh Sree Raman [a,b,c], Gaetano Nucifora [a], Darryl P. Leong [d], Christian Marx [a], Ranjit Shah [a,b,c], Richard J. Woodman [e], Payman Molaee [f], Masoumeh Gh. Shirazi [g,h], Andrew D. McGavigan [a,b], Carmine G. De Pasquale [a,b], Joseph B. Selvanayagam [a,b,c,*]

[a] College of Medicine and Public Health, Flinders University, Australia
[b] Department of Cardiovascular Medicine, Flinders Medical Centre, Australia
[c] Cardiac Imaging Research Group, South Australian Health & Medical Research Institute, Australia
[d] The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada
[e] Flinders Centre of Epidemiology and Biostatistics, College of Medicine and Public Health, Flinders University, Australia
[f] Southern Adelaide Local Health Network, Australia
[g] Faculty of Health and Medical Sciences, University of Adelaide, Australia
[h] Department of Cardiology, Royal Adelaide Hospital, Australia

ARTICLE INFO

ABSTRACT

Background: Presence of myocardial fibrosis in well-established non-ischaemic dilated cardiomyopathy (NIDCM) is associated with adverse clinical outcomes. However, the impact of myocardial fibrosis at first presentation in NIDCM, and its long-term association with left ventricular (LV) dysfunction, heart failure (HF) and ventricular arrhythmia (VA) remains unclear. We investigated whether the presence of myocardial fibrosis quantified by late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) at presentation, is independently associated with long-term major adverse cardiovascular events (MACE) in patients with first presentation NIDCM.

Methods: Consecutive patients with a first diagnosis of NIDCM were recruited. Patients underwent LGE-CMR at baseline. Replacement myocardial fibrosis by LGE-CMR was quantified by experienced observers blinded to patient outcome. MACE was defined as a composite end-point including cardiac death, HF rehospitalisation and the occurrence of sustained VA.

Results: Fifty-one patients with first presentation NIDCM were included, of which 49 (96%) had follow up and outcome data. Median follow up was 8.2 years. Both the LGE positive and LGE negative groups had similar clinical characteristics at follow up. In univariate Cox regression analysis, positive LGE was associated with MACE (HR:3.44; 95% CI:1.89 to 6.24, p-value < 0.001) and HF rehospitalisation (HR:2.89; 95% CI:1.42 to 5.85, p-value = 0.003). In multivariate Cox regression, positive LGE-CMR was independently associated with MACE (HR:3.53; 95% CI:1.51 to 8.27, p-value = 0.004) and HF rehospitalisation (HR:3.07; 95% CI:1.24 to 7.59, p-value = 0.015).

Conclusions: The presence of myocardial fibrosis in first presentation NIDCM is independently associated with an increased risk of HF rehospitalisation, at long term follow-up.

1. Introduction

Non-ischaemic dilated cardiomyopathy (NIDCM) is characterised by impairment in systolic left ventricular (LV) function following a non-ischaemic, mechanistically variable but often poorly defined, myocardial insult. Clinical management of this condition is generally determined by the patient's symptoms, the electrocardiogram and the LV ejection fraction (LVEF) on echocardiogram. This approach has limitations in specifically identifying patients who are unlikely to respond to medical therapy or who are at higher risk of sudden cardiac death [1]. This is graphically displayed in a study of 8000 patients with ischaemic and non-ischaemic cardiomyopathy and LVEF < 40%, which demonstrated that despite the use of modern therapies, there is a 20% mortality rate at 2 years [2].

Over the last two decades cardiovascular magnetic resonance (CMR) has been utilised in the diagnostic assessment of patients with NIDCM. Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) has shown that ≈30% of patients with established NIDCM

* Corresponding author at: Department of Cardiovascular Medicine, Flinders Medical Centre, Adelaide, South Australia 5042, Australia.
  E-mail address: Joseph.Selvanayagam@flinders.edu.au (J.B. Selvanayagam).

have mid-wall LGE, which represents replacement fibrosis, and that this provides incremental prognostic information to LVEF [3]. In particular, multiple studies have shown that the presence of LGE-CMR in the NIDCM population portends to increase risk of heart failure events, ventricular arrhythmias (VA) and sudden cardiac death (SCD) [4,5].

All previous studies have focused on patients with established NIDCM for a duration of at least 6 months. Whether mid-wall LGE identifies high-risk patients at their first presentation NIDCM, is unknown. Using a unique cohort of patients with first presentation NIDCM, we have previously demonstrated that the presence of mid-wall LGE at presentation leads to adverse LV remodelling at 5 months [6]. Whether this is associated with adverse clinical outcome over the long term is unknown. Accordingly, we investigated whether first presentation NIDCM with LGE-CMR is associated with major adverse clinical events (MACE) over a long-term follow up. We hypothesized that the presence of myocardial fibrosis as detected by LGE-CMR in patients at their first presentation of NIDCM would be independently associated with MACE.

2. Methods

2.1. Study population and protocol

The details of the subject characteristics, inclusion and exclusion criteria have been previously reported [6]. In summary, consecutive patients were recruited from 3 university hospitals where they had presented with new onset heart failure (HF) with NIDCM diagnosed after routine clinical, echocardiography and coronary angiography work-up. The inclusion criterion was the presence of LV ejection fraction ≤ 45% at baseline echocardiography or CMR. Exclusion criteria included the diagnosis of significant coronary artery disease (defined as >70% luminal stenosis in an epicardial coronary artery at angiography, non-invasive stress imaging suggestive of ischemia, or prior myocardial infarction), severe valvular heart disease, thyroid dysfunction, infiltrative cardiomyopathy or extra-cardiac systemic features to suggest sarcoidosis or amyloidosis, chemotherapy-induced cardiomyopathy, hypertrophic cardiomyopathy, peripartum cardiomyopathy, alcohol-induced cardiomyopathy and myocarditis. Myocarditis was excluded by the absence of classic clinical features, the presence of normal serum troponin I concentration at presentation, and by the lack of evidence of myocardial oedema on T2-weighted CMR [7]. Patients were excluded from CMR when renal impairment (eGFR < 60 mL/min), or other conventional CMR contra-indications were present. HF therapies were administered in accordance with the 2008 European Society of Cardiology (ESC) guidelines of diagnosis and treatment of acute and chronic heart failure [8].

Research LGE-CMR and transthoracic echocardiography was performed within two weeks of presentation with first diagnosis NIDCM when clinically stable. To minimise variability due to loading conditions, CMR and echocardiography were performed in immediate succession for each individual. All patients provided written and informed consent to the study which was approved by the relevant Human Research Ethic Committee.

2.2. Cardiac magnetic resonance protocol and analysis

The full protocol has been described elsewhere [6]; in brief, CMR was performed using commercially available 1.5T machines (Siemens Avanto, Erlangen, Germany or Philips Intera, Best, The Netherlands). Electrocardiographically-gated steady-state free precession imaging of the LV in the short-axis plane was undertaken. LGE-CMR imaging was undertaken 10 min following intravenous administration of gadolinium-DTPA 0.1 mmol/kg using an inversion-recovery segmented gradient echo sequence. CMR data analysis was performed by 2 experienced (SCMR Level 3) observers, using commercially available software (CAAS MRV Version 3.3, PIE, Netherlands) [6,9]. Any disagreements were adjudicated by a third observer.

2.3. Clinical outcomes data

The primary study endpoint was the total number of MACE. MACE was defined as the composite of cardiac death, acute unplanned HF hospitalisation and the occurrence of ventricular arrhythmia (VA). VA events are defined as nonfatal ventricular fibrillation (VF), sustained ventricular tachycardia (VT) requiring external cardioversion or appropriate therapy by implantable cardioverter defibrillator (ICD) device triggered by VF or VT. VA that occurred during acute HF hospitalisations or leading to sudden cardiac death was not included and was separated from total VA event. Relevant clinical information (including new significant valvular disease or myocardial infarction) in the interim period was obtained annually from the outpatient follow up clinical notes. Outcome, clinical events and mortality data were obtained from a state-wide hospital database with clinical information coded according to the international classification of diseases. Adjudication was made by two physicians blinded to CMR results with an overall third senior cardiologist involved when first two cardiologists disagreed.

2.4. Statistical analysis

All analysis was performed in Stata version 14.2 (StataCorp, College Station, Texas, USA). The association of LGE was separately assessed on overall mortality, overall MACE (cardiac death, HF hospitalisation or VT/VF) and each type of MACE using log-rank analysis, univariate and multivariate Cox regression. Subjects were followed from their date of enrolment until the end date of the study (31st October 2017) or until the date of death if this was earlier. Subjects with more than one MACE continued in the study so that multiple events per subject were possible. Standard errors were adjusted for within-subject correlation using the cluster(id) vce(robust) option in Stata. For each of the outcomes, univariate Cox regression was used to test for unadjusted associations. Then, variables that were significant at $p < 0.20$ were entered into a multivariate Cox regression model. For consistency across outcomes, age and RV ejection fraction (RVEF) were included as adjustment variables in all models as these were each significant ($p < 0.05$) at the univariate level for MACE (all events). The assumption of proportional hazards for the overall model and LGE variable alone were tested using the proportional hazards test based on the Schoenfeld residuals. The effect of LGE was considered significant when $p < 0.05$. The estimated survival rates by LGE status was shown using unadjusted Kaplan-Meier curves with log-rank p-values. In a sensitivity analysis, the association with LGE and each non-mortality outcome (VT/VF, rehospitalisation and all MACE) was assessed using only the first event for each patient.

3. Results

3.1. Clinical characteristics

Follow up data were available in 49 (96%) patients. Tables 1a and 1b show the clinical characteristics of these patients. Seventeen (35%) patients had myocardial fibrosis (LGE positive) at baseline CMR. LGE was found in the mid-wall or at the insertion point of the right ventricular free wall and the interventricular septum. No ischaemic pattern of LGE was observed in this cohort. In total there was cumulative follow up of 321 years. Both the LGE positive and LGE negative groups were well matched for age, sex, rhythm and QRS duration, as well as baseline echocardiography and CMR variables prior to study enrolment (Table 1a). At follow up (median time 72 months for LGE positive group and 75 months for LGE negative group) there was no difference in echocardiographic LVEF ($p = 0.756$) and no new development of significant valvular heart disease or myocardial infarction. Seven patients (five LGE positive) had ICD implanted for primary prevention while two patients (one LGE positive) for secondary prevention. In addition, no significant difference in HF medication (loop diuretics, beta-blockers, angiotensin-converting enzymes or angiotensin receptor blockers (ACEi/ARB) and mineralocorticoid receptor antagonist (MRA)) was noted between the LGE positive and LGE negative groups (Table 1b).

3.2. Myocardial fibrosis (positive LGE CMR) and outcomes

Patients were followed-up for a median duration of 8.2 years (interquartile range 7.1–9.1 years) with a maximum follow up of 9.4 years. The presence of myocardial fibrosis was associated with increased risk of sustaining an index primary end point. Overall, 30 MACE events occurred amongst 10 of 17 patients (59%) with LGE and 17 MACE events in 10 of 32 patients (31%) without LGE. On Kaplan-Meier analysis, LGE was associated with a higher occurrence of MACE (log-rank $p < 0.001$) (Fig. 1a). Within this composite end point, a total of 19 recorded HF hospitalisations occurred in 9 of 17 patients (53%) with LGE and 13 HF hospitalisation events in 7 of 32 patients (22%) without LGE. In patients with multiple HF rehospitalisation events, the median duration between each acute rehospitalisations was 337 days. On Kaplan-Meier analysis, LGE was associated with HF hospitalisation (log-rank $p = 0.002$) (Fig. 1b). Moreover, there were 9 documented VA events in 3 of 17 patients (18%) with LGE in contrast to 2 VA events in 2 of 32 patients (6%) without LGE. On Kaplan-Meier analysis, LGE was associated with increased VA events (log-rank $p = 0.001$) (Fig. 1c). Both positive and negative LGE group had 2 patients with cardiac mortality. In the group with LGE the 2 cardiac deaths were due to sudden cardiac death. In the group without LGE, one patient died of sudden cardiac death and the other died of

Table 1a
Characteristics of NIDCM patients at baseline.

Characteristics	LGE positive (N = 17)	LGE negative (N = 32)	P-value
Age (years)	61 (54–67)	57 (49–66)	0.475
Male gender, n (%)	13 (76%)	22 (69%)	0.724
AF, n (%)	5 (29%)	7 (22%)	0.589
QRS duration (ms)	118 (94–142)	97 (82–111)	0.115
Median NT-pro BNP (ng/l)	720 (609–2870)	683 (446–3718)	0.771
Baseline ECHO LVEF (%)	29 (24–33)	29 (24–34)	0.98
ECHO LAVi	40 (29–50)	38 (29–47)	0.769
CMR LVEF (%)	20 (15–26)	26 (23−30)	0.057
CMR LV EDVi (ml/m^2)	121 (94–147)	107 (90–124)	0.3796
CMR LV ESVi (ml/m^2)	94 (72–115)	78 (64–92)	0.205
CMR LV Mass Index (g/m^2)	69 (53–86)	78 (64–92)	0.409
CMR RVEF (%)	38 (27–49)	45 (39–51)	0.283
CMR RV EDVi (ml/m^2)	64 (48–79)	63 (52–73)	0.925
CMR RV ESVi (ml/m^2)	38 (25–50)	33 (19–32)	0.518

Legend: AF = atrial fibrillation, NT-pro BNP = N-terminal pro-brain natriuretic peptide, LGE = late gadolinium enhancement, ECHO = echocardiogram, LAVi = left atrial volume index, LVEF = left ventricular ejection fraction, RVEF = right ventricular ejection fraction, EDVi = end-diastolic volume index, ESVi = end-systolic volume index, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker.

myocardial infarction. The presence of LGE was not associated with increased cardiac mortality (log-rank *p* = 0.47) (Fig. 1d).

In Cox regression analysis (Table 2a), the independent variables considered for inclusion into the model in addition to LGE were age, QRS duration, atrial fibrillation (AF), N-terminal pro-brain natriuretic peptide (NT-pro-BNP), echocardiography and CMR parameters. In univariate analysis Cox regression analysis, LGE was predictive of MACE (HR: 3.44; 95% CI: 1.89 to 6.24, *p*-value < 0.001), HF hospitalisation (HR: 2.89; 95% CI: 1.42 to 5.85, p-value = 0.003) and VA events (HR: 8.4; 95% CI: 1.81 to 39.7, p-value = 0.007) (Table 2b). Variables with *p* < 0.20 were included in the multivariate cox regression model (Table 2a). LGE was significantly and independently associated with total MACE (HR: 3.53; 95% CI: 1.51 to 8.27, p-value = 0.004) and HF hospitalisation (HR: 3.07; 95% CI: 1.24 to 7.59, p-value = 0.015) but not with VA events and cardiac death (Table 2b).

In the sensitivity analysis using the first event for each patient only, the multivariate hazard ratio was reduced for MACE (HR = 2.22, *p* = 0.0168 versus HR = 3.53, *p* = 0.004) but almost identical for HF rehospitalisation (HR = 3.22, *p* = 0.069 versus HR = 3.07, *p* = 0.015). The analysis for first VA event was identical since all of the subjects included in the previous analysis had only 1 event (41 subjects of whom 3 had 1 VT/VF). The smaller number of events in the sensitivity analysis of MACE (14 versus 30) resulted in much wider confidence intervals for the estimated hazard ratio and the non-significant *p*-value.

4. Discussion

This study shows that LGE in patients at first presentation with NIDCM is independently associated with increased heart failure rehospitalisation for almost a decade after diagnosis. Heart failure

Table 1b
Characteristics of NIDCM patients at follow-up.

Characteristics	LGE Positive (N = 17)	LGE Negative (N = 32)	P-value
Follow up ECHO LVEF (%)	45 (38–52)	46 (37–55)	0.756
(Median time to ECHO follow up)	(72 months)	(75 months)	
Frusemide (%)	43%	47%	0.867
Beta-blocker (%)	86%	87%	0.952
ACEi/ARB (%)	57%	73%	0.448
Spironolactone (%)	57%	67%	0.665
Sacubitril/Valsartan (%)	14%	0%	0.98

Legend: ECHO = echocardiogram, LVEF = left ventricular ejection fraction, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker.

events are associated with the presence of essentially pre-diagnosis replacement myocardial fibrosis, thereby representing a group who may warrant more aggressive therapy and intensified follow up. This is evident with a recent study demonstrating that the presence of myocardial fibrosis predicts unfavourable long-term survival in heterogeneous population of new-onset of HF [10]. Additionally, our findings increase the clinical impetus for aggressive management of patients at risk of heart failure or those with asymptomatic left ventricular dysfunction where the syndrome of chronic heart failure has not yet evolved. Our study further highlights the long-term implications of myocardial fibrosis in a well-described population with first presentation NIDCM.

We found that the presence of mid-wall LGE on the presentation CMR scan (performed within the first 2 weeks after clinical presentation) was independently associated with MACE, being driven mainly by a higher rate of HF hospitalisations. It is likely that this observation is explained by reduced reverse remodelling to HF treatment in patients having LGE, as demonstrated in our previous study of the same cohort [6]. Our unique, prospective, longitudinally followed cohort study links presentation mid-wall LGE and the lack of echocardiographic LVEF improvement at 5 months to long term MACE, comprising mainly of HF hospitalisation's. Importantly, while NIDCM presentation can occur at any age, most patients are first seen between ages 20 and 50 years [11], thereby magnifying the potential benefit of risk stratification allowing targeted and optimised medical therapy.

Initial studies focusing on patients with established NIDCM of at least 12 months duration have demonstrated that LGE was the sole independent predictor of cardiovascular hospitalisation and death [12,13]. In the largest study to date, Halliday et al. reported a remarkably similar prevalence of LGE of 34.3% [14]. This study of 874 patients with NIDCM demonstrated that patients with myocardial fibrosis on LGE are more likely to have significant VA events and death [14]. The same group prospectively studied patients with NIDCM with an LVEF ≥ 40% and demonstrated an increased risk of SCD in patient with presence of LGE [15]. A recent meta-analysis has validated the presence of myocardial fibrosis detected via LGE-CMR in NIDCM as an independent predictor of MACE (HR 2.88; *p* < 0.001) and VA/SCD (HR 4.32; *p* < 0.001) [16].

The association of HF hospitalisation with LGE in first presentation NIDCM may largely reflect the relative frequency of this endpoint, however the independent association with a marker of symptomatic heart failure needs to be acknowledged and is potentially mechanistically instructive. NIDCM is generally a global pathogenic process. Autopsy data has shown the substrate for diffuse fibrosis is perivascular and interfibre fibrosis [17]. Furthermore, the pressure-volume overload and wall stress would lead to compensatory process that mainly affects the middle circumferential myocardial layer [18,19]. Hence mid-wall LGE could potentially represent the final pathway of these aforementioned patho-physiological mechanisms [20]. Recent advancements in CMR parametric T1 mapping techniques which were not available at study enrolment, enables the quantitative assessment of diffuse myocardial fibrosis [21,22]. This technique has demonstrated that besides the presence of LGE, the abnormalities in native T1 times are independent markers of all-cause mortality, HF death and HF hospitalisations [23].

Whilst the prior studies looked at patients with established NIDCM, our study focused on the long-term outcome of consecutive patients with first presentation NIDCM. We found a remarkably similar incidence of LGE at NIDCM presentation (35%) to the vast literature on established NIDCM [12–14]. This essentially represents "pre-diagnosis" fibrosis highlighting the significant duration of pre-clinical disease in NIDCM and providing impetus for study of preventative therapy in high-risk subgroups (e.g. genotypic positive familial cardiomyopathy carriers). These findings have potential important clinical implications. A reliable early marker of poor outcome as well as both heart failure and ventricular arrhythmic events could be used to rationalise early and intensified treatment to patients most in need. Previous animal models have shown that angiotensin II receptor blocker neprilysin

a: Positive LGE was associated with higher MACE

b: Positive LGE was associated with higher HF Hospitalisations

c: Positive LGE was associated with higher VA

d: Positive LGE was not associated with cardiac deaths

Fig. 1. a: Positive LGE was associated with higher MACE. b: Positive LGE was associated with higher HF Hospitalisations. c: Positive LGE was associated with higher VA. d: Positive LGE was not associated with cardiac deaths.

inhibitor (ARNI) have attenuating effects on cardiac fibrosis and cardiac remodelling [24,25]. Hence, this could potentially reverse or blunt the progression of first presentation or even at risk NIDCM – an important direction for future research, in which hard clinical endpoints might be examined.

It is increasingly recognised that myocardial scar induced re-entry arrhythmias make up the majority of VA in the cardiomyopathic heart [26,27]. Intuitively, scar represented by LGE would be expected to be mechanistically associated with VA events. The lack of independent association between LGE and life-threatening VA seen in our study, goes against

Table 2a
Cox regression analyses for MACE.

Variable	Univariate		Multivariate*	
	HR (95% CI)	p-Value	HR (95% CI)	p-Value
LGE	3.44 (1.89–6.24)	p < 0.001	3.53 (1.51–8.27)	0.004
Age (years)	0.97 (0.95–1.00)	0.016	0.99 (0.96–1.02)	0.615
QRS duration (ms)	1.00 (0.99–1.01)	0.497		
AF	2.09 (1.13–3.86)	0.019	1.47 (0.63–3.42)	0.375
NT-pro BNP	1.00 (0.99–1.00)	0.990		
ECHO LAVi	1.00 (0.97–1.04)	0.814		
CMR LVEF (%), per 1 SD	0.86 (0.60–1.24)	0.417		
CMR LV EDVi (ml/m^2), per 1 SD	1.11 (0.80–1.54)	0.538		
CMR LV ESVi (ml/m^2), per 1 SD	1.19 (0.84–1.67)	0.323		
CMR LV Mass Index (g/m^2), per 1 SD	0.87 (0.63–1.19)	0.378		
CMR RVEF (%), per 1 SD	0.62 (0.42–0.91)	0.015	0.35 (0.02–7.57)	0.504
CMR RV EDVi (ml/m^2), per 1 SD	1.00 (0.68–1.49)	0.983		
CMR RV ESVi (ml/m^2), per 1 SD	1.33 (0.92–1.92)	0.129	0.61 (0.30–1.24)	0.171

Legend: AF = atrial fibrillation, NT-pro BNP = N-terminal pro-brain natriuretic peptide, LGE = late gadolinium enhancement, CMR = cardiovascular magnetic resonance, ECHO = echocardiogram, LAVi = left atrial volume index, LVEF = left ventricular ejection fraction, RVEF = right ventricular ejection fraction, EDVi = end-diastolic volume index, ESVi = end-systolic volume index, SD = standard deviation.
  * Model included all variables significant at p < 0.20 in univariate analysis.

Table 2b
Hazard ratios for LGE from univariate and multivariate Cox regression for each end point.

Outcome	LGE Status	Events	Univariate		Multivariate[a]	
			HR (95% CI)	p-value	HR (95% CI)	p-value
MACE	LGE +	30	3.44 (1.89–6.24)	p < 0.001	3.53 (1.51–8.27)	0.004
	LGE -	17				
Heart Failure Rehospitalisations	LGE +	19	2.89 (1.42–5.85)	0.003	3.07 (1.24–7.59)	0.015
	LGE -	13				
Ventricular Arrhythmia Events	LGE +	9	8.48 (1.81–39.72)	0.007	4.88 (0.39–60.54)	0.217
	LGE -	2				
Cardiac Death	LGE +	2	2.01 (0.28–14.31)	0.484	2.69 (0.17–42.55)	0.482
	LGE -	2				

Legend: LGE = late gadolinium enhancement, LGE + = LGE positive, LGE - = LGE negative.
[a] Adjusted for age, atrial fibrillation, cardiovascular magnetic resonance right ventricular ejection fraction (CMR RVEF), CMR RV end-systolic volume index (CMR RV ESVi).

prior findings in established NIDCM. This could be explained by the low number of patients or the low number of VA event observed in this observational study. Present day guidelines recommend primary prevention ICD implantation in NIDCM for those with LVEF < 35% [28,29]. However, the majority of patients who succumb to SCD have LVEF > 35%, hence, our tools of risk stratifying these patients for likelihood of SCD are poor [30]. Furthermore, Kober et al. have recently demonstrated that ICD implantation guided solely by LVEF may not confer a survival benefit in non-ischaemic cardiomyopathy [31]. Whilst randomised clinical trials are currently underway to answer the question of whether a CMR guided approach is superior to standard care in NIDCM patients with mild-moderate systolic dysfunction [32] and myocardial fibrosis, LGE-CMR has already shown utility in guiding implantation of cardiac resynchronisation therapy (CRT) devices [33,34]. In addition CRT with defibrillation (CRT-D) has been shown to be superior to CRT in non-ischaemic cardiomyopathy patients with myocardial fibrosis on LGE-CMR [35].

4.1. Study limitations

Our study has some limitations. Firstly, it is observational in nature and hence there may have been residual confounding due to differences in length of patient symptoms, patient characteristics and disease course prior to diagnosis that were not measured. In addition, the study was relatively small and there were only a small number of specific events, although the total number was similar to those observed in larger studies. Still a larger study could provide better understanding into patient symptoms and characteristics which may be clinically relevant. The low uptake of ACEi/ARB could confound this further. However, it could reflect the current clinical uncertainty on how the long term management of these patients should be. While the significant associations that were observed cannot have been underpowered, the low number of events for VA and mortality will have reduced the power for determining predictive capacity of LGE-CMR for these events. In addition there is a notable lack of a univariable association between outcomes and NTproBNP, LAVi and CMR LVEF which is likely due to the study being under powered. Similarly, although hazard ratios were similar for MACE and acute HF rehospitalisation, when we used first events only in the sensitivity analysis, the smaller number of events reduced our power still further. However, assuming that the point estimate for our observed effect were retained in future larger studies, a dataset with at least 30 first events would provide sufficient power to demonstrate a statistically significant association. In contrast, strengths of the study include its long follow up (to the best of our knowledge the longest study of this type), the well described population, and immediate follow-up after presentation allowing a unique, prospective, longitudinal link between LGE-CMR and HF rehospitalisation.

5. Conclusion

The presence of myocardial replacement fibrosis as detected by CMR-LGE is independently associated with an increased risk of HF rehospitalisation in first presentation NIDCM. This finding has potential therapeutic implications in the heart failure management of patients with first presentation NIDCM.

References

[1] A.R. Patel, C.M. Kramer, Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy, J. Am. Coll. Cardiol. Img. 10 (10 Pt A) (2017) 1180–1193.

[2] J.J.V. McMurray, M. Packer, A.S. Desai, J. Gong, M.P. Lefkowitz, A.R. Rizkala, et al., Angiotensin–neprilysin inhibition versus enalapril in heart failure, N. Engl. J. Med. 371 (11) (2014) 993–1004.

[3] J.A. McCrohon, J.C. Moon, S.K. Prasad, W.J. McKenna, C.H. Lorenz, A.J. Coats, et al., Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance, Circulation 108 (1) (2003) 54–59.

[4] A. Gulati, A. Jabbour, T.F. Ismail, K. Guha, J. Khwaja, S. Raza, et al., Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy, JAMA 309 (9) (2013) 896–908.

[5] A. Di Marco, I. Anguera, M. Schmitt, I. Klem, T.G. Neilan, J.A. White, et al., Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis, JACC Heart Fail. 5 (1) (2017) 28–38.

[6] D.P. Leong, A. Chakrabarty, N. Shipp, P. Molaee, P.L. Madsen, L. Joerg, et al., Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography, Eur. Heart J. 33 (5) (2012) 640–648.

[7] M.G. Friedrich, U. Sechtem, J. Schulz-Menger, G. Holmvang, P. Alakija, L.T. Cooper, et al., Cardiovascular magnetic resonance in myocarditis: a JACC white paper, J. Am. Coll. Cardiol. 53 (17) (2009) 1475–1487.

[8] K. Dickstein, A. Cohen-Solal, G. Filippatos, J.J. McMurray, P. Ponikowski, P.A. Poole-Wilson, et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM), Eur. Heart J. 29 (19) (2008) 2388–2442.

[9] L.E. Hudsmith, S.E. Petersen, J.M. Francis, M.D. Robson, S. Neubauer, Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging, J. Cardiovasc. Magn. Reson. 7 (5) (2005) 775–782.

[10] A. Gulati, A.G. Japp, S. Raza, B.P. Halliday, D.A. Jones, S. Newsome, et al., Absence of myocardial fibrosis predicts favorable long-term survival in new-onset heart failure: a cardiovascular magnetic resonance study, Circ. Cardiovasc. Imaging 11 (9) (2018), e007722.

[11] G.W. Dec, V. Fuster, Idiopathic dilated cardiomyopathy, N. Engl. J. Med. 331 (23) (1994) 1564–1575.

[12] R.G. Assomull, S.K. Prasad, J. Lyne, G. Smith, E.D. Burman, M. Khan, et al., Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy, J. Am. Coll. Cardiol. 48 (10) (2006) 1977–1985.

[13] K.C. Wu, R.G. Weiss, D.R. Thiemann, K. Kitagawa, A. Schmidt, D. Dalal, et al., Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy, J. Am. Coll. Cardiol. 51 (25) (2008) 2414–2421.

[14] B.P. Halliday, A.J. Baksi, A. Gulati, A. Ali, S. Newsome, C. Izgi, et al., Outcome in dilated cardiomyopathy related to the extent, location, and pattern of late gadolinium enhancement, J. Am. Coll. Cardiol. Img. (2018) https://doi.org/10.1016/j.jcmg.2018.07.015 [Epub ahead of print].

[15] B.P. Halliday, A. Gulati, A. Ali, K. Guha, S. Newsome, M. Arzanauskaite, et al., Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction, Circulation 135 (22) (2017) 2106–2115.

[16] A.N. Ganesan, J. Gunton, G. Nucifora, A.D. McGavigan, J.B. Selvanayagam, Impact of late gadolinium enhancement on mortality, sudden death and major adverse cardiovascular events in ischemic and nonischemic cardiomyopathy: a systematic review and meta-analysis, Int. J. Cardiol. 254 (2018) 230–237.

[17] W.C. Roberts, R.J. Siegel, B.M. McManus, Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients, Am. J. Cardiol. 60 (16) (1987) 1340–1355.

[18] W.K. Laskey, M.S.J. Sutton, G. Zeevi, J.W. Hirshfeld Jr., N. Reichek, Left ventricular mechanics in dilated cardiomyopathy, Am. J. Cardiol. 54 (6) (1984) 620–625.

[19] K.M. Borow, A. Neumann, R.H. Marcus, P. Sareli, R.M. Lang, Effects of simultaneous alterations in preload and afterload on measurements of left ventricular contractility in patients with dilated cardiomyopathy: comparisons of ejection phase, isovolumetric and end-systolic force-velocity indexes, J. Am. Coll. Cardiol. 20 (4) (1992) 787–795.

[20] S. Bohl, R. Wassmuth, H. Abdel-Aty, A. Rudolph, D. Messroghli, R. Dietz, et al., Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease, Int. J. Card. Imaging 24 (6) (2008) 597–607.

[21] V.O. Puntmann, T. Voigt, Z. Chen, M. Mayr, R. Karim, K. Rhode, et al., Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy, J. Am. Coll. Cardiol. Img. 6 (4) (2013) 475–484.

[22] S. Nakamori, K. Dohi, M. Ishida, Y. Goto, K. Imanaka-Yoshida, T. Omori, et al., Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy, JACC Cardiovasc. Imaging 11 (1) (2018) 48–59.

[23] V.O. Puntmann, G. Carr-White, A. Jabbour, C.-Y. Yu, R. Gebker, S. Kelle, et al., T1-mapping and outcome in nonischemic cardiomyopathy: all-cause mortality and heart failure, JACC Cardiovasc. Imaging 9 (1) (2016) 40–50.

[24] Y. Suematsu, S. Miura, M. Goto, Y. Matsuo, T. Arimura, T. Kuwano, et al., LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice, Eur. J. Heart Fail. 18 (4) (2016) 386–393.

[25] T.G. von Lueder, B.H. Wang, A.R. Kompa, L. Huang, R. Webb, P. Jordaan, et al., Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy, Circ. Heart Fail. 8 (1) (2015) 71–78.

[26] S. Nakahara, R. Tung, R.J. Ramirez, Y. Michowitz, M. Vaseghi, E. Buch, et al., Characterization of the arrhythmogenic substrate in ischemic and nonischemic cardiomyopathy: implications for catheter ablation of hemodynamically unstable ventricular tachycardia, J. Am. Coll. Cardiol. 55 (21) (2010) 2355–2365.

[27] H.H. Hsia, D.J. Callans, F.E. Marchlinski, Characterization of endocardial electrophysiological substrate in patients with nonischemic cardiomyopathy and monomorphic ventricular tachycardia, Circulation 108 (6) (2003) 704–710.

[28] A.M. Russo, R.F. Stainback, S.R. Bailey, A.E. Epstein, P.A. Heidenreich, M. Jessup, et al., ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance, J. Am. Coll. Cardiol. 61 (12) (2013) 1318–1368.

[29] S.G. Priori, C. Blomstrom-Lundqvist, A. Mazzanti, N. Blom, M. Borggrefe, J. Camm, et al., 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), Eur. Heart J. 36 (41) (2015) 2793–2867.

[30] K. Narayanan, K. Reinier, A. Uy-Evanado, C. Teodorescu, H. Chugh, E. Marijon, et al., Frequency and determinants of implantable cardioverter defibrillator deployment among primary prevention candidates with subsequent sudden cardiac arrest in the community, Circulation 128 (16) (2013) 1733–1738.

[31] L. Køber, J.J. Thune, J.C. Nielsen, J. Haarbo, L. Videbæk, E. Korup, et al., Defibrillator implantation in patients with nonischemic systolic heart failure, N. Engl. J. Med. 375 (13) (2016) 1221–1230.

[32] J.B. Selvanayagam, T. Hartshorne, L. Billot, S. Grover, G.S. Hillis, W. Jung, et al., Cardiovascular magnetic resonance-GUIDEd management of mild to moderate left ventricular systolic dysfunction (CMR GUIDE): study protocol for a randomized controlled trial, Ann. Noninvasive Electrocardiol. 22 (4) (2017).

[33] F. Leyva, P.W. Foley, S. Chalil, K. Ratib, R.E. Smith, F. Prinzen, et al., Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance, J. Cardiovasc. Magn. Reson. 13 (2011) 29.

[34] Taylor RJ, Umar F, Panting JR, Stegemann B, Leyva F. Left ventricular lead position, mechanical activation, and myocardial scar in relation to left ventricular reverse remodeling and clinical outcomes after cardiac resynchronization therapy: a feature-tracking and contrast-enhanced cardiovascular magnetic resonance study. Heart Rhythm. 13(2): 481–489.

[35] F. Leyva, A. Zegard, E. Acquaye, C. Gubran, R. Taylor, P.W.X. Foley, et al., Outcomes of cardiac resynchronization therapy with or without defibrillation in patients with nonischemic cardiomyopathy, J. Am. Coll. Cardiol. 70 (10) (2017) 1216–1227.